Press Releases 2010

02/2010	IDEA ANNOUNCES NEW CHIEF EXECUTIVE OFFICER
Press Releases 2009
10/2009	IDEA UPDATES ON DIRACTIN® (KETOPROFEN IN TRANSFERSOME® GEL) STATUS
04/2009	IDEA REPORTS RESULTS FROM A PROSPECTIVE 3 YEARS PHASE III STUDY OF DIRACTIN® (KETOPROFEN IN TRANSFERSOME® GEL)
02/2009	US PATENT OFFICE GRANTS A NEW PATENT TO IDEA AG, WHICH ALSO COVERS THE TARGETED ANALGESIC PRODUCT DIRACTIN® (KETOPROFEN IN TRANSFERSOME® GEL)

Press Releases 2008

12/2008	IDEA AG COMPLETES RECRUITMENT IN TWO CLINICAL STUDIES WITH DIRACTIN® (KETOPROFEN IN TRANSFERSOME® GEL), INCLUDING THE BIGGEST GERMAN BIOTECH STUDY TO DATE
11/2008	IDEA AG REPORTS DATA OF A 12-MONTH COMPARATIVE STUDY OF THE TARGETED ANALGESIC DIRACTIN® (KETOPROFEN IN TRANSFERSOME® GEL) VERSUS NAPROXEN AND GIVES DEVELOPMENT UPDATE
07/2008	IDEA AG GIVES AN UPDATE ON THE DEVELOPMENT OF DIRACTIN®, THE TARGETED ANALGESIC
05/2008	IDEA AG RECEIVES TWO MILESTONE PAYMENT S ($37 MILLION) FROM PARTNER ALPHARMA FOR ITS INNOVATIVE TARGETED ANALGESIC, DIRACTIN®

Press Releases 2007

09/2007	IDEA AG CONCLUDES LICENCE AGREEMENT FOR ITS INNOVATIVE TARGETED ANALGESIC, DIRACTIN®, WITH ALPHARMA
05/2007	IDEA AG SUBMITS MARKETING APPLICATION FOR ITS INNOVATIVE TARGETED ANALGESIC, DIRACTIN®, TO EMEA

Press Releases 2006

11/2006	IDEA AG RECEIVES APPROVABLE LETTER FROM SWISSMEDIC FOR IDEA-033, A NOVEL CARRIER-BASED, TARGETED ANALGESIC, FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF OSTEOARTHRITIS
08/2006	IDEA AG ANNOUNCES SUCCESSFUL COMPLETION OF ITS PIVOTAL PH III STUDY IN EUROPE AND REACQUISITION OF RIGHTS TO THE TARGETED ANALGESIC IDEA-033 IN NORTH AMERICA
02/2006	CELTIC PHARMA LICENSES TARGETED DRUG DELIVERY TECHNOLOGY AND DERMATOLOGICAL PRODUCT PORTFOLIO FROM IDEA AG

Press Releases 2005

11/2005	IDEA AG PRESENTS POSITIVE PH III DATA FOR IDEA-033
09/2005	IDEA AG ANNOUNCES ENCOURAGING INTERIM RESULTS OF PH III PROGRAM FOR PAIN THERAPEUTIC PRODUCT IDEA-033
09/2005	CELTIC PHARMA ACQUIRES STAKE IN IDEA AG
05/2005	IDEA AG STARTS PHASE III STUDY WITH IDEA-033
02/2005	IDEA AG STARTS PHASE II STUDY WITH IDEA-070 FOR TREATMENT OF VARIOUS INFLAMMATORY SKIN DISEASES

Press Releases 2004

11/2004	IDEA AG CONTINUES TO STRENGTHEN ITS IP POSITION
09/2004	IDEA AG STARTS PHASE III STUDY WITH IDEA-033 FOR TREATMENT OF PERIPHERAL PAIN
07/2004	IDEA AG RECEIVES MILESTONE PAYMENT FOR THE SUCCESS OF ADVANCED CLINICAL STUDY RESULTS WITH AN INNOVATIVE, TARGETED PAIN THERAPEUTIC
05/2004	IDEA-070 SHOWS EXCELLENT EFFICACY IN THE TREATMENT OF SKIN BURNS
02/2004	IDEA AG STARTS PHASE I STUDY WITH NEW PRODUCT FOR TREATMENT OF SKIN INFLAMMATION AND SKIN PAIN

go to top | /\ back /\

Impressum

©

AG